Pomalidomide-d4
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Pomalidomide-d4
Description:
Pomalidomide-d4 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<Product Name Alternative:
CC-4047-d4UNSPSC:
12352005Hazard Statement:
H360Target:
Apoptosis; Isotope-Labeled Compounds; Ligands for E3 Ligase; Molecular GluesType:
Isotope-Labeled CompoundsRelated Pathways:
Apoptosis; Others; PROTACApplications:
Cancer-programmed cell deathField of Research:
CancerPurity:
96.38Solubility:
10 mM in DMSOSmiles:
O=C1N(C2C(NC(C([2H])([2H])C2([2H])[2H])=O)=O)C(C3=C(N)C=CC=C31)=OMolecular Formula:
C13H7D4N3O4Molecular Weight:
277.27Precautions:
H360References & Citations:
[1]Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54 (4) :683-7.; Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 a|[2]Hernandez-Ilizaliturri FJ, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11 (16) :5984-92.|[3]Yuan Xiao Zhu, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54 (4) :683-7.; Hernandez-Ilizaliturri FJ1Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Isotope-Labeled CompoundsClinical Information:
No Development ReportedIsoform:
CereblonCAS Number:
[1416575-78-4]
